Literature DB >> 7912948

Effect of antagonizing residual neuromuscular block by neostigmine and atropine on postoperative vomiting.

A J Boeke1, J J de Lange, B van Druenen, J J Langemeijer.   

Abstract

Eighty patients undergoing outpatient surgery under general anaesthesia were allocated randomly to two groups: in group A residual neuromuscular block was antagonized with a mixture of neostigmine 1.5 mg and atropine 0.5 mg; in group B spontaneous recovery was allowed. The patients were assessed after operation in hospital and 24 h after discharge. We found a significant difference (P < 0.05) in requirements for antiemetic therapy with a smaller need in the group which received neostigmine (in group A four of 40 patients received an antiemetic compared with 12 in group B). There was no significant difference in frequency of nausea or vomiting between the two groups. The incidence of postoperative nausea was 14 in group A and 18 in group B and the number of patients with postoperative vomiting was 10 in group A and 15 in group B.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7912948     DOI: 10.1093/bja/72.6.654

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  3 in total

Review 1.  Neuromuscular transmission and its pharmacological blockade. Part 3: Continuous infusion of relaxants and reversal and monitoring of relaxation.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

2.  Comparison of Postoperative Gastrointestinal Motility of Sugammadex and Neostigmine in Patients Undergoing Robotic Thyroidectomy: A Retrospective Study.

Authors:  Min Jeong Lee; Duk-Hee Chun; Hee Jung Kong; Hye Jung Shin; Sunmo Yang; Na Young Kim
Journal:  J Clin Med       Date:  2022-05-22       Impact factor: 4.964

3.  Does neostigmine administration produce a clinically important increase in postoperative nausea and vomiting?

Authors:  Ching-Rong Cheng; Daniel I Sessler; Christian C Apfel
Journal:  Anesth Analg       Date:  2005-11       Impact factor: 6.627

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.